SCHEMBL16670210

SCHEMBL16670210

CCOCOc1ccc(O)c(O)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ESR1 P03372 1/20 0.36
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HIF1A Q16665 1/20 0.33
EPAS1 Q99814 1/20 0.33
GRM2 Q14416 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B2 P37059 1/20 0.32
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670438 0.81 BACE1 (0.40) MAPTALDH1A1KDM4EHPGDALOX15
SCHEMBL21647668 0.72 HIF1A (0.42) MAPTALDH1A1KDM4EHPGDALOX15
SCHEMBL1606904 0.71 ALDH1A1 (0.44) MAPTALDH1A1KDM4EHPGDALOX15
SCHEMBL1607641 0.71 SMN1; SMN2 (0.36) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
Ether SCHEMBL28772217 0.71 ALDH1A1 (0.43) MAPTALDH1A1KDM4EHPGDALOX15
SCHEMBL12476303 0.71 ESR1 (0.47) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL27771050 0.70 HTR1B (0.51) MAPTALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL8761088 0.70 MAPT (0.66) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL22542329 0.70 NCF1 (0.37)
SCHEMBL7861678 0.70 HIF1A (0.55) MAPTALDH1A1KDM4EHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861572-B1 IMPROVED PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LTD (IN) 2018-10-31 EP disclosed
US-9227948-B2 Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives NATCO PHARMA LIMITED (IN) 2016-01-05 US disclosed
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LIMITED (IN) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES DERA, XDH, F12 MAPT 2819/4885ALDH1A1 58/4885KDM4E 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.